| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04776850 Details | 2023-02-21 Interventional | 1 | 0 | Antibodies Antibodies, Mon… Antilymphocyte … Antineoplastic … BB 1101 Bortezomib Busulfan Cyclophosphamid… Dexamethasone Dexamethasone a… Fludarabine Fludarabine pho… Immunoglobulins Immunoglobulins… Mycophenolic Ac… Rho(D) Immune G… Rituximab Tacrolimus Thymoglobulin gamma-Globulins Anemia, Sickle … Hemoglobinopath… Thalassemia beta-Thalassemi… Beta Thalassemi… Sickle Beta 0 T… Sickle Beta Plu… Sickle Beta Tha… Sickle Cell Dis… Sickle Cell-SS … | Competing protocol opened in Adult SCT that will include pediatric patients and is now
multi-center. No patients enrolled on study. - | |||
| NCT04746495 Details | 2023-02-21 Interventional | 4 | 0 | Eplerenone Hypertension | Issues relate to COVID-19 and staffing challenges, as well as very tight finances. - | |||
| NCT04155580 Details | 2023-02-21 Interventional | 1 | 68 | Decitabine Decitabine and … Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Myeloid L… | Study halted prematurely and will not resume; participants are no longer being examined or
receiving intervention - | |||
| NCT03602781 Details | 2023-02-21 Interventional | 3 | 0 | Nitric Oxide Familial Primar… Hypertension Pulmonary Arter… | Decision not to proceed with Study - | |||
| NCT03386721 2017-003182-94 Details | 2023-02-21 Interventional | 2 | 256 | Antibodies Atezolizumab Gemcitabine Vinorelbine Uterine Cervica… Advanced/Metast… | The Sponsor discontinued the development of Simlukafusp alfa due to portfolio prioritization,
not due to any safety, efficacy, or quality issues. - | |||
| NCT03135860 Details | 2023-02-21 Interventional | 1 | 7 | Nitric Oxide Hypertension Hypertension, P… Lung Diseases Lung Diseases, … Pulmonary Disea… COPD Chronic Obstruc… Pulmonary Hyper… | This was an exploratory open-label study and has met its initial objectives - | |||
| NCT02807454 Details | 2023-02-21 Interventional | 2 | 37 | Daratumumab Dexamethasone Durvalumab Pomalidomide Multiple Myelom… Neoplasms, Plas… | Health Authority request due to class effect This study stopped enrolling participants on 05-Sep-2017 and was terminated earlier than planned on 03-Jan-2022. This results disclosure report provides outputs from the Simon Stage 1: D2 and PD3 arms. Simon Stage 2: D2 did not enroll any participants. | |||
| NCT02725372 Details | 2023-02-21 Interventional | 3 | 207 | Nitric Oxide Hypertension Pulmonary Arter… | Trial stopped for futility Planned Interim Analysis resulted in early termination due to futility, leading to small numbers of study participants analyzed. Analysis is based on Part 1 Blinded Treatment Period (up to 18 Weeks) only. | |||
| NCT01769027 Details | 2023-02-21 Interventional | 2 | 0 | Anti-Bacterial … Azithromycin Immunoglobulins… Penicillins Sertraline Pandas | No participants enrolled - | |||
| NCT01700569 2012-000774-31 Details | 2023-02-21 Interventional | 1 | 24 | Folic Acid Leucovorin Levoleucovorin Temozolomide Astrocytoma Glioblastoma Grade IV Astroc… | changing the standard of care - | |||
| NCT05730673 Details | 2023-02-17 Interventional | 2 | 0 | Leronlimab Colorectal Neop… CCR5 Colorectal Canc… Metastatic Microsatellite … | No participants enrolled - | |||
| NCT04965714 Details | 2023-02-16 Interventional | 2 | 0 | Nivolumab Carcinoma Carcinoma, Hepa… Resectable Hepa… | 0 patient accrual - | |||
| NCT04606563 Details | 2023-02-16 Interventional | 3 | 341 | Azilsartan medo… Candesartan Candesartan cil… Eprosartan Irbesartan Losartan Olmesartan Telmisartan Valsartan COVID-19 Communicable Di… Coronavirus Inf… Infections Severe Acute Re… Covid19 SARS-CoV Infect… | DSMC recommendation due to futility - | |||
| NCT04485065 Details | 2023-02-16 Interventional | 1 | - | Azacitidine Myelodysplastic… Preleukemia Syndrome | Suspended for changes in development strategy - | |||
| NCT04326764 Details | 2023-02-16 Interventional | 3 | 52 | Panobinostat Leukemia, Myelo… Myelodysplastic… Preleukemia Acute Myeloid L… Myelodysplastic… | Change of marketing authorisation holder - | |||
| NCT03678428 Details | 2023-02-16 Interventional | 3 | 92 | Floxuridine Irinotecan Leucovorin Oxaliplatin Colorectal Neop… Liver Metastase… Metastatic Colo… | Production halt of FUDR in China - | |||
| NCT02977286 Details | 2023-02-16 Interventional | 4 | 12 | Bisacodyl Bismuth subsali… Magnesium citra… Methylnaltrexon… Naloxegol Constipation Paralysis | Poor enrollment Limitations: One-third of the planned participants were enrolled, thus the study is substantially underpowered. Our results do not apply to non-medical patients. | |||
| NCT03663166 Details | 2023-02-15 Interventional | 1/2 | 19 | Ipilimumab Nivolumab Carcinoma, Non-… | Increased SAE occurrence per PI - | |||
| NCT04507373 Details | 2023-02-14 Interventional | 4 | 3 | Simvastatin Muscle Cramp Muscle Weakness Spasm Ache Statin Adverse … Weakness, Muscl… | No grant obtained. Enrolled participants were not assigned to the intervention and was study
terminated - | |||
| NCT03928275 Details | 2023-02-14 Interventional | 2/3 | 0 | Aldesleukin BCG Vaccine Interleukin-2 Melanoma Cutaneous Metas… | Withdrawn prematurely. - |